Foghorn Therapeutics Inc.
FHTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 13, 2026 | Evercore ISI | $3.00(+54%) | $1.95 | TheFly | |
| Oct 2, 2026 | H.C. Wainwright | Andrew Fein | $5.00(+71%) | $2.92 | StreetInsider |
| Oct 2, 2026 | Guggenheim | $5.00(+71%) | $2.92 | TheFly | |
| Oct 2, 2026 | Wedbush | Robert Driscoll | $2.00(-32%) | $2.92 | TheFly |
| Oct 1, 2026 | Stifel Nicolaus | Laura Prendergast | $5.00(+87%) | $2.67 | TheFly |
| Feb 17, 2026 | Jefferies | $12.00(+116%) | $5.55 | TheFly | |
| Dec 18, 2025 | BTIG | $11.00(+137%) | $4.64 | TheFly | |
| Dec 3, 2025 | Stifel Nicolaus | $12.00(+170%) | $4.44 | TheFly | |
| Dec 17, 2024 | H.C. Wainwright | Foghorn Therapeutics to $ | $13.00(+108%) | $6.26 | TheFly |
| Sep 24, 2024 | Morgan Stanley | Vikram Purohit | $9.00(-3%) | $9.32 | StreetInsider |
| Aug 19, 2024 | Evercore ISI | Gavin Clark-Gartner | $20.00(+219%) | $6.26 | TheFly |
| Jan 5, 2023 | BMO Capital | $20.00(+206%) | $6.53 | Benzinga | |
| Nov 21, 2022 | Morgan Stanley | $14.00(+78%) | $7.87 | Benzinga | |
| Aug 23, 2022 | Morgan Stanley | Vikram Purohit | $15.00(+38%) | $10.89 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | downgrade | Buy →Neutral | Oct 2, 2026 |
| Guggenheim | maintain | Buy | Oct 2, 2026 |
| TD Cowen | downgrade | Buy →Hold | Oct 2, 2026 |
| Wedbush | downgrade | Outperform →Neutral | Oct 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 2, 2026 |
| Wedbush | maintain | Outperform | Mar 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 10, 2026 |
| Jefferies | maintain | Buy | Feb 17, 2026 |
| JMP Securities | maintain | Market Outperform | May 15, 2025 |
| JMP Securities | maintain | Market Outperform | Apr 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2024 |
| Jefferies | maintain | Buy | Dec 16, 2024 |
| Morgan Stanley | maintain | Equal Weight | Sep 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| Wedbush | maintain | Outperform | Aug 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2024 |
| Wedbush | maintain | Outperform | Apr 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 10, 2024 |
| Wedbush | maintain | Outperform | Mar 8, 2024 |
| Morgan Stanley | maintain | Equal Weight | Nov 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 7, 2023 |
| Morgan Stanley | maintain | Equal Weight | Jul 6, 2023 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.10 | $-0.24 | $16.1M | $6.8M |
| May 7, 2026 | $-0.29 | $-0.28 | $3.3M | $7.9M |
| Mar 11, 2026 | $-0.34 | $-0.28 | $9.2M | $10.2M |
| Nov 5, 2025 | $-0.25 | $-0.31 | $8.2M | $9.5M |
| Aug 5, 2025 | $-0.28 | $-0.31 | $7.6M | $8.2M |
| May 14, 2025 | $-0.30 | $-0.30 | $6.0M | $6.2M |
| Mar 6, 2025 | $-0.30 | $-0.43 | $2.9M | $8.7M |
| Nov 4, 2024 | $-0.31 | $-0.42 | $7.8M | $8.1M |
News
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Foghorn Therapeutics (FHTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $FHTX--FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. (“Foghorn” or the “Company”) (NASDAQ: FHTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data.
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform Pipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.…
The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.